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Abstract
Background—The ability of interventions to affect declining β-cell function in screen-detected 
type 2 diabetes are poorly described. The Early Diabetes Intervention Program (EDIP; 
ClinicalTrials.gov NCT01470937) was a randomized study based on the hypothesis that 
improving postprandial glucose excursions with acarbose would slow the progression of fasting 
hyperglycemia in screen-detected type 2 diabetes. In EDIP, the effect of acarbose plus lifestyle 
advice on progression of fasting hyperglycemia over a 5 year period was not greater than that of 
placebo. However, there was an early glucose lowering effect of the trial. The objective of the 
current secondary analysis was to describe β-cell function changes in response to glucose-
lowering.
Methods—Participants were overweight adult subjects with screen-detected type 2 diabetes. β-
cell function was measured using hyperglycemic clamps and oral glucose tolerance testing. The 
primary outcome was the change in β-cell function from baseline to Year 1, the time point where 
the maximal glucose-lowering effect was seen.
Results—At baseline, participants exhibited markedly impaired first-phase insulin response. 
Despite significant reductions in weight, FPG, and 2-hr PG, there was no clinically significant 
improvement in first-phase insulin response. Late-phase insulin responses declined despite 
beneficial glycemic effects of interventions.
Conclusions—Insulin secretion is already severely impaired in early, screen-detected type 2 
diabetes. Effective glucose-lowering intervention with acarbose was not sufficient to improve 
insulin secretion or halt the decline of β-cell function.
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INTRODUCTION
The pathophysiology of type 2 diabetes is characterized by decreased insulin action and 
progressive deterioration in insulin secretion relative to insulin sensitivity 1, 2. The Early 
Diabetes Intervention Program (EDIP; registered on ClinicalTrials.gov, NCT01470937) was 
a randomized study based on the hypothesis that improving postprandial glucose excursions 
with acarbose would slow the progression of screen-detected type 2 diabetes, defined as the 
development of frank fasting hyperglycemia, over up to 5 years of follow-up.
The study inclusion criteria included BMI ≥25 kg/m2, no history of type 2 diabetes, and no 
use of glucose-lowering agents. Participants were diagnosed with type 2 diabetes during 
study screening, defined as having a 2-hr oral glucose tolerance test (OGTT) plasma glucose 
(2-hr PG) value over 200 mg/dL and fasting plasma glucose (FPG) values between 100 and 
139 mg/dL. The mean hemoglobin A1c (HbA1c) of this screen-detected study population at 
baseline was (6.34 ± 0.64%), below the current HbA1c threshold for the diagnosis of 
diabetes. The primary study outcome of the EDIP trial was previously published 3: The 
effect of acarbose plus lifestyle advice on progression of fasting hyperglycemia over a 5 
year follow-up period was not greater than that of placebo plus lifestyle advice.
Here we describe in vivo β-cell function measured by OGTT and hyperglycemic clamp 
during the EDIP trial, and the effects of the interventions on β-cell function. In the EDIP 
trial, it was presumed that β-cell dysfunction was associated with the screen-detected type 2 
diabetes phenotype of primarily post-prandial hyperglycemia, and the hypothesis that 
improved β-cell function would be associated with reduction in post-prandial hyperglycemia 
was pre-specified for secondary analyses. In a similar study in a Dutch population with 
prediabetes, there was no benefit of acarbose-related glucose lowering on insulin secretion 
or insulin sensitivity during a three-year treatment period 4. Here we have evaluated whether 
there was any improvement in β-cell functioning among EDIP participants and whether this 
was related to the glucose-lowering effect of study interventions. We also evaluated whether 
baseline anthropomorphic and metabolic parameters determined study-related changes in β-
cell function in the EDIP trial.
METHODS
The study was approved by the institutional review boards of Indiana University School of 
Medicine and Washington University School of Medicine and all subjects provided written 
informed consent for the research. Inclusion and exclusion criteria, and general methods for 
the EDIP trial have been previously published 3. Participants were recruited from the 
surrounding communities using a process that included OGTT screening of asymptomatic 
individuals without known diabetes. Briefly, a registered dietitian counseled subjects on an 
appropriate diet for type 2 diabetes and subjects began either acarbose or an identical 
placebo based on a blinded randomization. Study drug was initiated at a dose of 25 mg once 
daily with the evening meal, then titrated at weekly intervals by 25 mg daily to the 
maximum dose of 100 mg t.i.d. with meals. Study drug was down-titrated as needed in 
subjects who complained of gastrointestinal side effects. Efforts were made to reach a daily 
dosage of at least 50 mg t.i.d..
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The insulin secretion responses to enteral (OGTT) and parenteral (hyperglycemic clamp) 
glucose stimuli were assessed. OGTT measurements of β-cell function were performed at 
baseline, and at the end of years 1 and 2 in participants who had not yet met the primary 
outcome (FPG ≥140 mg/dL). Hyperglycemic clamp procedures were performed in a 
randomly assigned subset (50%) of the participants at baseline, and at the end of year 1 and 
year 2. We analyzed OGTT and hyperglycemic clamp data from three time points: baseline, 
year 1, and year 2. Maximal acarbose effectiveness for glucose-lowering was observed in 
the first year of the study (120 min OGTT glucose at baseline 236.5 ± 3.0 mg/dL, at Year 1 
201.3±5.0, p<0.0001). Therefore, this was the optimal time point to evaluate whether 
glucose-lowering was associated with improved β-cell function. The primary endpoint of 
interest in the current analyses was change in β-cell function from baseline to year 1.
At study initiation participants were admitted to the General Clinical Research Center for a 
2-day study visit. OGTT and hyperglycemic clamp studies were done in the fasting state on 
separate days. OGTTs were performed in all participants using a standard 75-g glucose load 
with blood samples collected for measurement of plasma glucose and insulin at −10, 0, 30, 
60, and 120 minutes. Glucose concentrations were determined using a glucose oxidase 
method (YSI, Yellow Springs, OH). Insulin was measured by radioimmunoassay (Linco 
Research). HbA1C was measured by immunoturbidimetric assay (Roche Diagnostics, 
Indianapolis, IN).
For hyperglycemic clamp studies, fasting samples for plasma glucose and insulin were 
obtained at −10 and 0 min. A priming glucose bolus and then a maintenance glucose 
infusion, calculated by modification of the DeFronzo and Andres method 5, was infused to 
rapidly bring the plasma glucose to 200 mg/dL, then adjusted according to bedside glucose 
measurements every 5 minutes to maintain plasma glucose at this level for 4 hours. Samples 
for insulin were obtained every 2 minutes for the first 10 minutes of glucose infusion, at 15 
and 30 minutes, and then at 30 minute intervals for the remainder of the 4-hour study.
Calculations
For both procedures, fasting insulin values were the average of the two baseline values. The 
OGTT-derived measures of β-cell function were the insulinogenic index (IGI) [(30 minute − 
fasting insulin [μU/mL]) ÷ (30 minute − fasting glucose [mg/dL])] reflecting OGTT early-
phase insulin response; and the insulin area under the curve (AUC; calculated using the 
trapezoidal rule) reflecting OGTT late-phase insulin response. The hyperglycemic clamp-
derived insulin secretion measures included clamp first-phase insulin (mean of values 
between +2 and +10 minutes), and clamp second-phase insulin (mean insulin concentrations 
during the final hour of the clamp).
These measures of β-cell function exhibited the expected hyperbolic inverse relationships 
with measures of insulin sensitivity (not shown). Insulin sensitivity parameters used were 
inverse fasting insulin for OGTT-derived β-cell function parameters, and clamp-derived ISI 
for clamp-derived β-cell function parameters (calculation below). A disposition index was 
calculated to adjust insulin secretion for insulin sensitivity measures from the OGTT (oral 
disposition index, oDI) and hyperglycemic clamp (clamp disposition index, cDI) 6. The oDI 
was calculated as (IGI x inverse fasting insulin) * 100. An insulin sensitivity index (ISI) was 
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derived from the steady state of the hyperglycemic clamp as (mean glucose-space adjusted 
glucose disposition rate ÷ mean insulin concentration during the last h of the clamp) ×1007. 
The cDI was calculated as first-phase insulin × ISI. Results for late or second-phase insulin 
secretion were presented as unadjusted values (Table 1, baseline correlations) or with 
statistical adjustment for the appropriate insulin sensitivity parameter (inverse fasting insulin 
for OGTT data and inverse ISI for clamp data; Tables 2–4) due to collinearity with the 
measures of insulin sensitivity that precluded similar derivations of disposition indices.
Statistical analysis
Parallel analyses were performed for early and late phase insulin secretion parameters 
derived from the OGTT, and for first- and second-phase insulin secretion parameters derived 
from the hyperglycemic clamp. Over the course of the study, study participants in both 
groups had changes in weight, FPG, and 2-hr PG concentrations. Also, we examined weight, 
FPG, 2-hr PG, sex, and age as potential determinants of baseline β-cell function and of 
treatment-induced changes in β-cell function.
Many of the parameters evaluated had right-skewed distributions. Baseline correlation 
analyses were therefore performed using nonparametric testing (Spearman’s rho). 
Regression modeling was performed on untransformed variables. The primary outcome of 
interest was the change in each parameter of β-cell function, calculated as the year 1 value 
minus baseline. Univariate models were constructed against each of these change variables, 
followed by multivariable models. First the full set of parameters of interest was entered into 
the model, and then a forward stepwise procedure was applied to identify the parameters 
with the strongest effects on change in β-cell function. Effect sizes for these models were 
expressed as standardized beta coefficients (effect size per SD of the independent variable) 
to facilitate comparisons of magnitude of effect. SPSS software was used to perform all 
statistical analysis (Version 20, IBM). Two-sided p values <0.05 were considered 
statistically significant.
RESULTS
Baseline demographic and metabolic characteristics of the study participants are shown in 
Table 1. There were no significant differences in OGTT- or clamp-derived measures of 
insulin secretion between the treatment groups at baseline (Table 1).
Glucose and insulin excursions in response to OGTT and clamp testing are shown in Figure 
1. OGTT and clamp measurements of β-cell function were performed at the end of years 1 
and 2, only in patients who had not yet met the primary outcome (FPG ≥ 140 mg/dL). 
Therefore, subjects included in this analysis either had glucose lowering or failed to rise 
above this threshold. In both acarbose and placebo treatment groups OGTT FPG, 2-hr PG, 
and stimulated insulin values were significantly reduced from baseline at years 1 and 2. The 
reduction in FPG was significantly greater in acarbose versus placebo (−8.6 mg/dL versus 
−3.4 mg/dL, p=0.041, Year 1). The reduction in 2-hr PG was not significantly different 
between treatment groups (−26.5 mg/dL acarbose, −20.2 mg/dL placebo, p=0.12, Year 1). 
Pooled data from both treatment groups are provided in Figure 1, presenting OGTT and 
clamp data from baseline, Year 1 and Year 2. Clamp insulin excursion, measured under 
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circumstances where the glycemic load is held constant, did not change significantly in 
either treatment group after 1 year of study intervention (Figure 1, bottom right panel). As is 
evident in that panel, first-phase insulin production measured during the clamp was 
markedly impaired at baseline (with essentially no peak and a notably delayed maximal 
response) and did not improve after 1 year of study intervention.
OGTT early-phase insulin secretion and clamp-derived first-phase insulin secretion adjusted 
for insulin sensitivity (oDI and cDI) at baseline and follow-up are shown in Figure 2. There 
were no treatment group differences in oDI or cDI measures between the treatment groups at 
baseline (not shown). There was a modest increase in oDI with acarbose at Year 1, not 
significantly different from baseline (Figure 2 upper left panel). There was no difference in 
oDI change over time between treatment groups. The cDI was significantly increased with 
time on treatment (Figure 2 upper right panel), but the change over time was not 
significantly different between the acarbose and placebo groups. Further, the absolute values 
for these first-phase responses remained very low..
OGTT late-phase insulin secretion and clamp-derived second-phase insulin secretion at 
baseline and follow-up are also shown in Figure 2 (lower panels). Both the OGTT late-phase 
insulin (AUC) and clamp second-phase insulin responses decreased over time despite 
decreasing FPG and 2-hr PG values. There were no significant differences in change over 
time between the acarbose group and the placebo group (not shown).
Study interventions had significant effects on weight. Baseline BMI did not differ between 
treatment group (Table 1). In placebo-treated subjects, baseline weight was 98 ± 21 kg, and 
at Year 1 95± 21 (p=0.001 versus baseline) and Year 2 94± 16 (p=0.01 versus baseline). In 
acarbose-treated subjects, baseline weight was 97± 20 kg, and at Year 1 93± 20 (p<0.001 
versus baseline) and Year 2 93± 20 (p<0.001 versus baseline). There were no significant 
differences in weight between treatment groups at any of these time points.
Spearman correlations of phenotypic characteristics of the subjects with OGTT and clamp-
derived measures of β-cell function at baseline are available in the Appendix (Appendix 
Table 1). Higher baseline OGTT early-phase insulin (oDI) and late-phase insulin (AUC) 
values (i.e. better β-cell function) were associated with female sex (oDI r=0.197, p=0.005; 
AUC r=0.150, p=0.033), lower baseline FPG (oDI r=−0.239, p=0.001), lower 2-hr PG (oDI 
r=−0.220, p=0.002; AUC r=−0.206, p=0.003), and lower baseline HbA1c (oDI r=−0.168, 
p=0.018). Higher baseline OGTT late-phase insulin (AUC) was also associated with higher 
baseline weight (r=0.194, p=0.006). Similarly, higher baseline first-phase clamp insulin 
secretion (cDI) values were associated with lower baseline FPG (r=−0.321, p=0.002), lower 
2-hr PG (r=−0.267, p=0.012), and lower baseline HbA1c (r=−0.397, p<0.001). Higher 
baseline clamp second-phase insulin was associated with higher baseline weight (r=0.320, 
p=0.001), lower age (r=−0.220, p=0.032), lower FPG (r=−0.228, p=0.025) and lower 2-hr 
PG (r=−0.303, p=0.003).
There were 121 participants with FPG < 126 mg/dL at baseline. Of these, 67 were assigned 
to placebo (mean ± SD FPG 113 ± 10 mg/dL) and 54 were assigned to acarbose (FPG 110 ± 
10 mg/dL, p = 0.023). There was no difference between those who were treated with 
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acarbose or placebo in FPG lowering at the end of Year 1 (−4.0 ± 13 versus −0.5 ± 15 
mg/dL, p=0.228). There was also no difference in mean change at Year 1 in the OGTT IGI 
(0.03 ± 0.73 versus −0.22 ± 0.73, p=0.166), OGTT disposition index (0.67 ± 3.28 versus 
0.62 ± 6.18, p=0.972), OGTT insulin AUC (−1059 ± 4467 versus −2461 ± 5286, p=0.245), 
clamp phase 1 insulin (−9.1 ± 16.5 versus 4.4 ± 32.6, p=0.213), clamp disposition index 
(15.3 ± 66.3 versus 20.0 ± 209.8, p=0.942), or clamp phase 2 insulin (−18.8 ± 30.5 versus 
−18.9 ± 70.0, p=0.996).
Univariate determinants of the change in measures of OGTT- and clamp-derived insulin 
secretion at Year 1 are shown in Table 2. These responses exhibited a mean increase in 
values. Change in OGTT early-phase insulin secretion (oDI) was inversely related to 
baseline OGTT IGI, HbA1c, and weight. Change in first-phase clamp insulin secretion (cDI) 
was directly related to higher baseline weight; this is opposite to the observed relationship 
between oDI and lower weight. Late phase/second-phase responses exhibited a mean 
decrease in values. Change in OGTT late-phase insulin (AUC) was inversely related to 
baseline insulin AUC, and directly related to baseline fasting insulin. Change in clamp 
second-phase insulin was inversely related to baseline second-phase insulin and change in 
insulin sensitivity. Pertinent to the main hypothesis being tested, the univariate relationships 
between change in glucose and change in β-cell function measures was directionally positive 
(direct association) for early phase measures, and directionally negative (inverse association) 
for late phase measures, but did not achieve statistical significance for any of these 
relationships.
Parameters that exhibited the strongest effects in determining change in insulin secretion 
when evaluated concurrently using multivariable analysis, unadjusted for insulin sensitivity 
are shown in Table 3 (Year 1 versus baseline). In these analyses neither the baseline fasting 
glucose values nor the change in fasting or 2-hr post-challenge glucose proved significantly 
associated with change in β-cell function. Baseline β-cell function measures were highly 
significant determinants of change for all measures tested, such that lower baseline measures 
were associated with greater decline in insulin secretion. Higher baseline weight was the 
only determinant of change in clamp first-phase insulin, and change in weight was inversely 
related to change in OGTT late-phase insulin (AUC). Insulin sensitivity (ISI) and change in 
ISI were directly associated with change in clamp second-phase insulin response.
DISCUSSION
We have characterized in vivo β-cell function measured by OGTT and hyperglycemic clamp 
in a population with early, screen-detected type 2 diabetes, and evaluated the effects of a 
glucose-lowering intervention on β-cell function. In aggregate, our findings indicate that β-
cell function is profoundly impaired in screen-detected type 2 diabetes, with essentially 
absent first-phase insulin response to acute hyperglycemia during the hyperglycemic clamp. 
Contrary to our hypothesis, there was no effect of acarbose to specifically improve β-cell 
function compared to placebo; This was not due to the study-related changes seen in the 
placebo group but rather to a true lack of relationship between changes in glucose and 
measures of β-cell function; even in univariate analyses there was no relationship of change 
in glucose with change in β-cell function. In fact, the study-related effects on glucose in the 
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placebo group magnify our ability to comment on the hypothesized beneficial effects of 
reducing glucose. Significant glucose reductions were associated with 1) no improvement in 
the poor clamp first-phase insulin response, 2) no improvement in OGTT early-phase insulin 
response adjusted for insulin sensitivity (oDI), and 3) statistically significant but 
physiologically unimportant increase in clamp first-phase insulin adjusted for insulin 
sensitivity (cDI). Further, the OGTT late-phase and clamp second-phase insulin responses 
declined over time despite glucose-lowering effects of the interventions. In univariate 
analyses, decreases in weight and insulin resistance influenced β-cell function, resulting in 
decreases in OGTT late-phase insulin secretion as the demand for insulin lessened with 
decreasing FPG and 2-hr PG. In multivariable analyses adjusting for changes in weight and 
insulin resistance the relationship between changes in glucose and changes in insulin 
secretion was no longer statistically significant. This implies that weight and insulin 
sensitivity are important determinants of changes in β-cell function. Overall these 
observations argue that, contrary to our hypothesis, treatment-related changes in glucose did 
not promote improvements in β-cell function in EDIP; however, we did observed modest 
changes that were due to non-glucose effects of randomized therapies.
Others have previously shown that the first-phase β-cell response is blunted in type 2 
diabetes and prediabetes 8–12, and we have further extended these observations. The 
Whitehall II prospective occupational cohort study has shown significant differences in 
measures of glycemia and markers of insulin sensitivity and secretion (fasting HOMA 
values) among normoglycemic individuals who went on to develop diabetes as compared 
with those who did not develop diabetes 13. Differences in glucose and insulin values, as 
well as trajectories of change in these values, are noted several years prior to the diagnosis 
of diabetes. These published findings further support our data.
Although the EDIP study was initiated in an era when dysglycemic states were defined 
differently than currently defined, it is clear that the study population, identified with FPG 
between 100 and 139 mg/dL and 2-hr PG > 200 mg/dL, already had significant β-cell 
impairment. Moreover, it has been observed that individuals with both impaired fasting 
glucose (IFG) and impaired glucose tolerance (IGT) rather than one or the other are at least 
twice as likely to progress to diabetes, with annualized incidence rates of progression of ~4–
6% for IGT, ~6–9% for IFG, and ~15–19% for IGT + IFG 14. We now know, from the US 
Diabetes Prevention Program trial among others, that prevention of progression to diabetes 
is dependent on baseline glucose values and on the achievement of normal glucose 
tolerance 15. Hence, the patient population selected for study in EDIP had more profound β-
cell dysfunction than was widely appreciated at the time, and therefore was evidently less 
likely to demonstrate a therapeutic effect either by acarbose or lifestyle modification. This 
study leaves unanswered the question whether glucose lowering alone is sufficient to reverse 
β-cell dysfunction in prediabetic populations with isolated IFG or isolated IGT, which 
inherently differ in their degree of β-cell dysfunction and perhaps in the pathophysiologic 
changes that underlie progressive metabolic dysfunction 16, 17.
The results of EDIP differ from the STOP-NIDDM study, a multi-centered trial of acarbose 
versus placebo conducted outside the U.S, which found acarbose to be superior to placebo 
for delaying the progression of dysglycemia after 3 months of therapy 18. The study 
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population in STOP-NIDDM was prediabetic at baseline as evidenced by lower mean FPG 
(~112 mg/dL) and 2-hr PG (~167 mg/dL). They also had lower BMI (~31 kg/m2). STOP-
NIDDM did not similarly measure β-cell function. However, these results and those from 
successful diabetes prevention programs using other treatment modalities suggest that 
populations with prediabetes do have a capacity to improve β-cell function, in contrast to the 
population with screen-detected diabetes studied in EDIP.
The 3-year Dutch Acarbose Intervention Study in Persons with Impaired Glucose Tolerance 
(DAISI) also investigated the effect of acarbose in persons with impaired glucose tolerance 
on glycemia and hyperglycemic clamp measures of β-cell function 4. The study population 
in the DAISI had a mean FPG of ~118 mg/dL, 2-hr PG of ~172 mg/dL, an even lower mean 
BMI than the STOP-NIDDM trial (~29 kg/m2). After 3 years, acarbose was associated with 
lower mean 2-h PG (−21 mg/dL, 95% CI: −37; −3), no difference in FPG, and an absolute 
risk reduction for diabetes of 6%. However, there was no measured treatment effect on 
insulin clamp-derived measures of insulin secretion or insulin sensitivity. This study used a 
lower dose of acarbose (50 mg three times daily). It is conceivable that a higher dose of 
acarbose in a population such as this could have further delayed the progression of 
dysglycemia with the potential for an improvement in β-cell function.
Although this particular glucose-lowering therapy (acarbose) was not sufficient to promote 
improvement in β-cell function in our population with screen-detected diabetes there is 
evidence that early pharmacological intervention with agents that target incretin effects on β-
cell functioning can potentially prevent or delay progression of diabetes. Acute 
improvements in functional β-cell capacity during treatment with dipeptidyl peptidase 
inhibitors, and glucagon-like peptide 1 (GLP-1) agonists have been demonstrated 19–21. 
Intensive insulin therapy in patients with newly diagnosed type 2 diabetes has been shown to 
be superior to oral hypoglycemic agents for achieving normoglycemia 22, and has been 
shown to have a durable effect to improve endogenous insulin secretion after therapy is 
stopped 22, 23. This suggests that it is imperative to identify if interventions earlier in the 
course of dysglycemia or prediabetes can further prevent or delay these progressive changes. 
It should be noted that in EDIP, despite having no benefit on measures of β-cell function, 
there was some improvement in glycemic measures with acarbose, and little progression in 
the placebo group likely related to dietary counseling 3. This highlights the benefit of 
participation in a clinical trial and dietary counseling, which is often overlooked, in patients 
with prediabetes and type 2 diabetes.
Over the course of the study, there was a modest increase in clamp first-phase insulin 
secretion adjusted for insulin sensitivity (cDI), and a decrease in OGTT late-phase insulin 
secretion. Increase in OGTT early-phase insulin (oDI) was associated with lower weight and 
lower HbA1c at baseline. Conversely, increase in the clamp-derived cDI was related to 
higher baseline weight, which may imply that weight loss during the study was important for 
increasing the acute insulin response to IV glucose. Changes in OGTT late-phase insulin 
(AUC) were primarily determined by baseline insulin values (lower baseline OGTT insulin 
AUC, higher baseline fasting insulin) and insulin sensitivity. Together these results are 
consistent with previous studies indicating that weight reduction, associated with improving 
insulin sensitivity, favorably affects β-cell function 24, 25. It is notable that these effects were 
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evident while glucose lowering per se was not related to changes in β-cell function in this 
population with screen-detected type 2 diabetes.
Our study had some limitations. Individuals who failed therapy during the study, defined as 
having a FPG ≥140 mg/dL, met the study end-point and were no longer followed on a yearly 
basis; so follow-up data presented here represents those whose diabetes did not significantly 
progress within the interval study period. The results of this study may only apply directly to 
adults with screen-detected type 2 diabetes detected via OGTT. The data were obtained from 
a clinical trial intervention using lifestyle recommendations and a single pharmaceutical 
agent (acarbose) that resulted in moderate reductions in glycemia. It should be noted that 
others have demonstrated glucose-lowering with acarbose to have a similar effect on HbA1c 
as metformin in patients with newly diagnosed type 2 diabetes 26. While these results may 
not be generalizable to populations being treated with more aggressive glucose reduction, 
they can likely be generalized to interventions that reduce glycemia overall without 
concurrent systemic effects of the agent to improve insulin sensitivity. The study 
interventions included lifestyle recommendations for both treatment groups, and produced 
significant improvements in metabolic parameters including FPG and 2-hr PG in the placebo 
group, minimizing the treatment benefits that could be attributed to acarbose. Although this 
biased against finding an acarbose-specific effect, this phenomenon functionally increased 
our power to evaluate the contributions of changes in glucose to changes in β-cell function, 
strengthening our conclusion that glucose lowering effects alone are not sufficient to 
produce recovery of β-cell function in adults with very early, screen-detected diabetes.
Despite these limitations, our study has important strengths. These include the combined use 
of OGTT and hyperglycemic clamp tests to evaluate β-cell function over several years of 
follow-up in a population with earlier diabetes than is typically found in clinical practice or 
clinical trials. The hyperglycemic clamp has been considered the established gold-standard 
procedure for measuring β-cell function, allowing for precise and reliable measurements of 
first- and second-phase glucose-stimulated insulin secretion. The OGTT delivers enteral 
glucose, stimulating incretin effects on β-cell function, while the hyperglycemic clamp 
singly addresses parenteral glucose-stimulated insulin secretion. Incretin effects on β-cell 
function are important factors in the regulation of β-cell function and impairments in the 
incretin system may contribute to progression of the diabetic state. Few studies have utilized 
these combined measures prospectively during treatment protocols, and further study to 
assess the utility of these measures (singly or in combination) in trials of β-cell preservation 
is warranted.
We conclude that individuals with early screen-detected diabetes already have marked β-cell 
dysfunction and that effective glucose-lowering was not sufficient to significantly improve 
β-cell function in this population. Consideration must be given to intervene earlier in the 
process of transition to diabetes, i.e. in the prediabetic stage, to restore or preserve β-cell 
function. Implementation of this recommendation will require randomized controlled studies 
of treatments that include adequate analysis of pertinent biologic measures in the prediabetes 
stage of the disease.
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Appendix Table 1
Spearman correlations of phenotypic characteristics with OGTT and hyperglycemic clamp 
measures of β cell function
Early-Phase OGTT 
Insulin Secretion 
oDI
Late-Phase OGTT 
Insulin Secretion 
OGTT AUCins
First-Phase Clamp 
Insulin Secretion 
cDI
Second-Phase 
Clamp Insulin 
Secretion Clamp 
Phase-2 Insulin
(n=204) p value (n=202) p value (n=87) p value (n=94) p value
Sex (F=1, M=0) 0.197 0.005 0.150 0.033 0.166 0.124 0.122 0.236
Age 0.052 0.461 0.032 0.650 −0.026 0.810 −0.220 0.032
Weight −0.070 0.320 0.194 0.006 −0.279 0.009 0.320 0.001
Fasting Glucose −0.239 0.001 −0.050 0.483 −0.321 0.002 −0.228 0.025
OGTT 2-hr Glucose −0.220 0.002 −0.206 0.003 −0.267 0.012 −0.303 0.003
HbA1c −0.168 0.018 −0.083 0.249 −0.397 <0.001 −0.176 0.088
Fasting Insulin−1 0.106 0.132 −0.720 <0.001 0.157 0.155 −0.599 <0.001
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Early-Phase OGTT 
Insulin Secretion 
oDI
Late-Phase OGTT 
Insulin Secretion 
OGTT AUCins
First-Phase Clamp 
Insulin Secretion 
cDI
Second-Phase 
Clamp Insulin 
Secretion Clamp 
Phase-2 Insulin
(n=204) p value (n=202) p value (n=87) p value (n=94) p value
Triglycerides −0.059 0.406 0.073 0.307 0.024 0.828 0.021 0.839
Total cholesterol 0.023 0.739 0.029 0.687 0.064 0.560 −0.131 0.101
HDL cholesterol 0.111 0.115 −0.176 0.012 0.125 0.253 −0.265 0.010
LDL cholesterol 0.045 0.524 0.031 0.665 0.038 0.732 −0.124 0.234
Non-HDL cholesterol 0.010 0.887 0.077 0.280 0.032 0.774 −0.068 0.518
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Figure 1. 
Glucose and insulin excursions in response to OGTT and hyperglycemic clamp testing at 
baseline (solid squares), after 1 year of treatment (open squares), and after 2 years of 
treatment (open circles). Change in OGTT FPG, 2-hr PG, and 2-hr insulin values from 
baseline to year 1, p<0.001.
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Figure 2. 
Measures of first-phase insulin secretion adjusted for insulin sensitivity (oDI and cDI) and 
second-phase insulin secretion (AUCins and phase 2 insulin) by treatment group during 
treatment. P values indicate comparisons across 1 or 2 years of intervention, as indicated by 
the horizontal bars; in all instances there was no significant treatment-specific effect.
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Table 1
Baseline Characteristics of the Study Population and OGTT and Clamp Measures of β-Cell Function 
According to Treatment Group
Acarbose
n=109
Placebo
n=110 p value
Gender
 Male 36 (33.0) 38 (34.6) 0.74
 Female 73 (67.0) 72 (65.4)
Race
 White 84 (77.1) 87 (79.1) 1.00
 Other Race 25 (22.9) 23 (20.9)
Age (years) 53.7 ± 11.0 53.7 ± 11.7 0.98
BMI (kg/m2) 35.1 ± 7.2 35.2 ± 7.1 0.83
HbA1c 6.4 ± 0.6 6.3 ± 0.6 0.84
OGTT measures of insulin secretion n=104 n=100
IGI 0.609 ± 0.726 0.508 ±0.534 0.26
Insulin AUC (μU/mL*min) 8619 ± 4712 9699 ± 7188 0.21
oDI 2.90 ± 2.50 3.08 ± 2.81 0.63
Clamp measures of insulin secretion n=47 n=48
1st-phase insulin (μU/mL) 26.5 ± 17.6 30.8 ± 28.2 0.39
2nd-phase insulin (μU/mL) 61.5 ± 39.2 83.3 ± 97.5 0.16
cDI 143 ± 55 157 ± 139 0.55
Data are n (%) or means ± SD.
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